TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

Journal of Clinical Investigation

Volumn 123, Issue 3, 2013, Pages 1348-1358

  Bhola, Neil E ^a   Balko, Justin M ^a   Dugger, Teresa C ^a   Kuba, María Gabriela ^a   Sánchez, Violeta ^a   Sanders, Melinda ^a   Stanford, Jamie ^a   Cook, Rebecca S ^a   Arteaga, Carlos L ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 8; LY 2157299; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; RNA; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; AUTOCRINE EFFECT; BREAST BIOPSY; CANCER CHEMOTHERAPY; CANCER STEM CELL; GENE EXPRESSION; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERLEUKIN-8; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; PACLITAXEL; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; QUINOLINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; SPHEROIDS, CELLULAR; TRANSFORMING GROWTH FACTOR BETA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874607100     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI65416     Document Type: Article

References (46)

1. Dent R, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 pt 1):4429-34. (Pubitemid 47219710)
2. Liedtke C, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275-1281.
3. Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983-3988. (Pubitemid 36418143)
4. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: Models and concepts. Annu Rev Med. 2007; 58:267-284. (Pubitemid 46706514)
5. McDermott SP, Wicha MS. Targeting breast cancer stem cells. Mol Oncol. 2010;4(5):404-419.
6. Li X, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100(9):672-679.
7. Mani S, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704-715. (Pubitemid 351636299)
8. Shipitsin M, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11(3):259-273. (Pubitemid 46349843)
9. Bierie B, Moses HL. Tumour microenvironment: TGF[beta]: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6(7):506-520. (Pubitemid 43980540)
10. Bierie B, et al. Transforming growth factor-β regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res. 2008;68(6):1809-1819. (Pubitemid 351416566)
11. Bueno L, et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-[beta] kinase antagonist, in mice. Eur J Cancer. 2008;44(1):142-150. (Pubitemid 350256941)
12. Zhong Z, et al. Anti-transforming growth factor β receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin Cancer Res. 2010;16(4):1191-1205.
13. Geiss GK, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotech. 2008;26(3):317-325. (Pubitemid 351355126)
14. Gonzalez-Angulo AM, et al. Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res. 2012;18(4):1109-1119.
15. Ginestier C, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555-567. (Pubitemid 350056407)
16. Conlin A, Seidman A. Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities. Clin Breast Cancer. 2008;8(3):215-223. (Pubitemid 351962142)
17. Hortobagyi G. Docetaxel in breast cancer and a rationale for combination therapy. Oncology (Williston Park). 1997;11(6 suppl 6):11-15.
18. Carey LA, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-2334. (Pubitemid 46698581)
19. Torrisi R, et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol. 2008;62(4):667-672.
20. Derynck R, Akhurst RJ, Balmain A. TGF-[beta] signaling in tumor suppression and cancer progression. Nat Genet. 2001;29(2):117-129. (Pubitemid 32952643)
21. Ginestier C, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest. 2010;120(2):485-497.
22. Xu R-H, et al. NANOG is a direct target of TGFbeta/activin-mediated SMAD signaling in human ESCs. Cell Stem Cell. 2008;3(2):196-206.
23. DaCosta Byfield S, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2004;65(3):744-752. (Pubitemid 38264042)
24. Ganapathy V, et al. Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer. 2010;9:122.
25. Inman GJ, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002;62(1):65-74. (Pubitemid 34680517)
26. Creighton C, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009;106(33):13820-13825.
27. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8(10):755-768.
28. Bruna A, et al. TGF-beta induces the formation of tumour-initiating cells in claudinlow breast cancer. Nat Commun. 2012;3:1055.
29. Chhipa RR, Bhat MK. Bystander killing of breast cancer MCF-7 cells by MDA-MB-231 cells exposed to 5-fluorouracil is mediated via Fas. J Cell Biochem. 2007;101(1):68-79. (Pubitemid 46652573)
30. Rody A, et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res. 2011;13(5):R97.
31. Charafe-Jauffret E, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009;69(4):1302-1313.
32. Bendre MS, et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res. 2005;65(23):11001-11009. (Pubitemid 41713370)
33. Kang Y, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A. 2005;102(39):13909-13914. (Pubitemid 41377677)
34. Bauer J, et al. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res. 2010;12(3):R41.
35. Azaro A, et al. The oral transforming growth factor-beta (TGF-ss) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study. ASCO Meeting Abstracts. 2012;30:2042.
36. Rodon Ahnert J, et al. First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma. ASCO Meeting Abstracts. 2011;29:3011.
37. Hawinkels LJAC, ten Dijke P. Exploring anti-TGF-β therapies in cancer and fibrosis. Growth Factors. 2011;29(4):140-152.
38. Janda E, et al. Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis. J Cell Biol. 2002;156(2):299-314.
39. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem. 2000;275(47):36803-36810. (Pubitemid 32002090)
40. Gupta J, Robbins J, Jilling T, Seth P. TGFbeta-dependent induction of Interleukin-11 and Interleukin-8 involves SMAD and p38 MAPK pathways in breast tumor models with varied bone metastases potential. Cancer Biol Ther. 2011;11(3):311-316.
41. Padua D, et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008;133(1):66-77. (Pubitemid 351442989)
42. Neve R, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10(6):515-527. (Pubitemid 44854747)
43. Hwang-Verslues WW, et al. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One. 2009;4(12):e8377.
44. Yoon C-H, et al. PTTG1 oncogene promotes tumor malignancy via epithelial to mesenchymal transition and expansion of cancer stem cell population. J Biol Chem. 2012;287(23):19516-19527.
45. Wang Y, et al. Transforming growth factor-[beta] regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene. 2011;30(12):1470-1480.
46. Hu Y, Smyth GK. ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347(1-2):70-78.